Zomedica Announces Letter From Robert Cohen, Interim CEO, Made Available to Shareholders in Connection With Special Virtual...
26 Octobre 2020 - 2:25PM
Zomedica Corp. (NYSE American: ZOM) announced today that the
following letter from Robert Cohen, Interim Chief Executive
Officer, has been made available to shareholders.
Dear Shareholders:
I am writing to you today with a single,
straightforward message -- please vote for the domestication
proposal described in our proxy materials for our virtual Special
Meeting to be held on December 15, 2020. Approval of the
domestication proposal will enable Zomedica to reincorporate the
company in Delaware, as opposed to its present incorporation in
Alberta, Canada.
Management believes that reincorporating your
company in Delaware will directly benefit shareholders by saving
approximately $500,000 per year in duplicative, unnecessary
compliance costs.
We believe that effecting the domestication also
will enhance shareholder value over the long term by, among other
things, making our company more attractive to institutional
investors who are more comfortable investing in a Delaware
corporation. In addition, our corporate offices and operations are
located in the United States and a large percentage of our
shareholders now are located there.
If your common shares are held by a broker, bank
or other intermediary, you will need to obtain a voting instruction
form from the organization that holds your common shares and follow
the instructions included on that form regarding how to instruct
the organization to vote your common shares.
Once again, I would appreciate your vote in favor
of the domestication. Your Board of Directors and management all
believe that it is in the best interests of Zomedica and our
shareholders.
Yours truly,
Robert Cohen
Additional Information and Where to Find
It This letter is for informational purposes only and does
not constitute an offer to buy or sell or the solicitation of an
offer to buy or sell any securities or a solicitation of any vote
or approval. This letter relates to the proposed domestication of
Zomedica Corp. (the “Company”). In connection with the proposed
domestication, the Company has filed a registration statement on
Form S-4, which includes a document that serves as a prospectus and
proxy circular of the Company (the “proxy circular/prospectus”),
and the Company may file other documents regarding the proposed
domestication with the U.S. Securities and Exchange Commission (the
“SEC”). No offering of securities shall be made, except by means of
a prospectus meeting the requirements of Section 10 of the U.S.
Securities Act of 1933, as amended. INVESTORS AND SECURITY HOLDERS
ARE URGED TO READ THE PROXY CIRCULAR/PROSPECTUS AND ANY OTHER
RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR
ENTIRETY, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT
SHAREHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING
THE PROPOSED DOMESTICATION. A definitive proxy circular/prospectus
has been sent to the Company’s shareholders. Investors and security
holders will be able to obtain these documents (when available)
free of charge from the SEC’s website at www.sec.gov. The documents
filed by the Company with the SEC may also be obtained free of
charge from the Company by requesting them by mail at Zomedica
Corp., 100 Phoenix Drive, Suite 180, Ann Arbor, Michigan 48108.
Participants in the Solicitation
The Company and its respective directors and executive officers and
other members of management and employees may be deemed to be
participants in the solicitation of proxies from the Company’s
shareholders in respect of the proposed domestication. Information
about the Company’s directors and executive officers is included in
the proxy circular/prospectus. Information regarding the persons
who may, under the rules of the SEC, be deemed participants in the
proxy solicitation and a description of their direct and indirect
interests, by security holding or otherwise, is contained in the
proxy circular/prospectus or will be contained in other relevant
materials that may be filed with the SEC regarding the proposed
domestication when they become available. Investors should read the
proxy circular/prospectus carefully before making any voting or
investment decisions. You may obtain free copies of these documents
from the SEC and the Company as indicated above.
No Offer or Solicitation This
letter shall not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act of 1933, as
amended.
About Zomedica Based in Ann
Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary
health company creating products for dogs and cats by focusing on
the unmet needs of clinical veterinarians. Zomedica’s product
portfolio will include innovative diagnostics and medical devices
that emphasize patient health and practice health. It is Zomedica’s
mission to provide veterinarians the opportunity to increase
productivity and grow revenue while better serving the animals in
their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica
Investor Relations Contact:
PCG Advisory Group Kirin Smith, COO
ksmith@pcgadvisory.com +1 646.863.6519
www.pcgadvisory.com
Zomedica Pharmaceuticals (TSXV:ZOM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Zomedica Pharmaceuticals (TSXV:ZOM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024